R
Raffaella Sordella
Researcher at Cold Spring Harbor Laboratory
Publications - 50
Citations - 18652
Raffaella Sordella is an academic researcher from Cold Spring Harbor Laboratory. The author has contributed to research in topics: Epidermal growth factor receptor & Erlotinib. The author has an hindex of 29, co-authored 50 publications receiving 17748 citations. Previous affiliations of Raffaella Sordella include Cornell University & Watson School of Biological Sciences.
Papers
More filters
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways
TL;DR: It is reported that mutant EGFRs selectively transduce survival signals on which NSCLCs become dependent; inhibition of those signals by gefitinib may contribute to the drug's efficacy.
Journal ArticleDOI
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
Kwak Eunice L,Raffaella Sordella,Daphne W. Bell,Godin-Heymann Nadia G,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,David R. Driscoll,Panos Fidias,Thomas J. Lynch,Sridhar K. Rabindran,John P. McGinnis,Allan Wissner,Sreenath V. Sharma,Kurt J. Isselbacher,Jeffrey Settleman,Daniel A. Haber +16 more
TL;DR: These findings suggest that one of these, HKI-272, may prove highly effective in the treatment of EGFR-mutant NSCLCs, including tumors that have become resistant to gefitinib or erlotinib.
Journal ArticleDOI
Protein Interaction Mapping in C. elegans Using Proteins Involved in Vulval Development
Albertha J.M. Walhout,Raffaella Sordella,Xiaowei Lu,James L. Hartley,Gary F. Temple,Michael A. Brasch,Nicolas Thierry-Mieg,Marc Vidal +7 more
TL;DR: A protein interaction mapping project is now feasible for C. elegans on a genome-wide scale and should contribute to the understanding of molecular mechanisms in this organism and in human diseases.
Journal ArticleDOI
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752
Gromoslaw A. Smolen,Raffaella Sordella,Beth Muir,Gayatry Mohapatra,Anne Barmettler,Heidi Archibald,Woo J. Kim,Ross A. Okimoto,Daphne W. Bell,Dennis C. Sgroi,James G. Christensen,Jeffrey Settleman,Daniel A. Haber +12 more
TL;DR: It is shown that gastric cancer cells with high-level stable chromosomal amplification of the growth factor receptor MET are extraordinarily susceptible to the selective inhibitor PHA-665752, which may identify a subset of epithelial cancers that are uniquely sensitive to disruption of this pathway.